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ABSTRACT
Mechanisms of Roux-en-Y gastric bypass (RYGB) surgery are not fully understood. This study aimed 
to investigate weight loss-independent bacterial and metabolic changes, as well as the absorption 
of bacterial metabolites and bile acids through the hepatic portal system following RYGB surgery. 
Three groups of obese Zucker (fa/fa) rats were included: RYGB (n = 11), sham surgery and body 
weight matched with RYGB (Sham-BWM, n = 5), and sham surgery fed ad libitum (Sham-obese, 
n = 5). Urine and feces were collected at multiple time points, with portal vein and peripheral blood 
obtained at the end of the study. Metabolic phenotyping approaches and 16S rRNA gene sequen-
cing were used to determine the biochemical and bacterial composition of the samples, respec-
tively. RYGB surgery-induced distinct metabolic and bacterial disturbances, which were 
independent of weight loss through caloric restriction. RYGB resulted in lower absorption of 
phenylalanine and choline, and higher urinary concentrations of host-bacterial co-metabolites 
(e.g., phenylacetylglycine, indoxyl sulfate), together with higher fecal trimethylamine, suggesting 
enhanced bacterial aromatic amino acid and choline metabolism. Short chain fatty acids (SCFAs) 
were lower in feces and portal vein blood from RYGB group compared to Sham-BWM, accompanied 
with lower abundances of Lactobacillaceae, and Ruminococcaceae known to contain SCFA produ-
cers, indicating reduced bacterial fiber fermentation. Fecal γ-amino butyric acid (GABA) was found 
in higher concentrations in RYGB than that in Sham groups and could play a role in the metabolic 
benefits associated with RYGB surgery. While no significant difference in urinary BA excretion, RYGB 
lowered both portal vein and circulating BA compared to Sham groups. These findings provide 
a valuable resource for how dynamic, multi-systems changes impact on overall metabolic health, 
and may provide potential therapeutic targets for developing downstream non-surgical treatment 
for metabolic disease.
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The incidence of obesity continues to grow at an 
unprecedented rate posing a global health crisis.1 
Bariatric surgery is currently the only effective 
treatment for morbid obesity, resulting in rapid 
and substantial weight loss that is sustained long- 
term.2 Roux-en-Y Gastric Bypass (RYGB) is 
amongst the most commonly performed bariatric 
procedures and has been shown to increase circu-
lating anorexigenic and glucoregulatory gut hor-
mone levels (e.g., glucagon-like peptide-1 (GLP-1) 
and peptide YY (PYY)), as well as to induce pro-
found systemic metabolic and the gut microbial 
changes.3,4 An increase in the relative bacterial 
abundance of Gammaproteobacteria and 
Verrucomicrobia in feces has consistently been 
reported in both human and animal models post 
RYGB.4–6 These gut bacterial changes in the RYGB- 
operated patients are persistent for up to 9 years 
post-operatively, and are considered to regulate 
host metabolism and fat mass.7 Furthermore, meta-
bolic phenotyping studies have revealed profound 
alterations in urinary host-microbial co- 
metabolites, such as phenylacetylglycine, phenyla-
cetylglutamine, 4-cresyl sulfate, and trimethyla-
mine N-oxide (TMAO), suggesting that RYGB 
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induces both compositional and functional changes 
of the gut microbiota.4,6 However, there remains 
a lack of understanding concerning weight loss- 
independent systemic metabolic changes over 
time. In addition, emerging evidence indicates 
that bile acids (BAs) play a key role in the mechan-
isms of bariatric surgery.8,9 BAs are cholesterol- 
derived molecules and aid in the absorption of diet-
ary fat. BAs, as ligands for the nuclear farnesoid 
X receptor (FXR), control their own synthesis and 
hepatic lipid metabolism.10 BAs also promote GLP- 
1 secretion from enteroendocrine cells11 and influ-
ence systemic metabolism by driving energy expen-
diture through activation of G-protein coupled 
receptor 5 (GPR5).12 BAs also regulate glucose 
metabolism by increasing insulin sensitivity and 
suppressing gluconeogenesis.10 Improved insulin 
sensitivity after RYGB has been linked to increased 
circulating secondary BAs, particularly glycodeoxy-
cholic acid.13 However, it is unclear how bariatric 
surgery influences the absorption of bile acids and 
bacterial metabolites. The portal vein is the point of 
exit for a multitude of host-microbe signaling 
molecules emanating from the gastrointestinal 
tract, but little is known about how the portal vein 
blood metabolome is affected by RYGB. Therefore, 
to address these issues, we studied fecal bacterial 
composition and a collection of biofluids from 
obese Zucker rats at multiple time points, as well 
as investigated the absorption of bile acids and 
bacterial metabolites in the portal vein blood fol-
lowing RYGB surgery.
Results
The effect of RYGB and caloric restriction on food 
intake, body weight and oral glucose tolerance
Twenty-one obese Zucker (fa/fa) rats were divided 
into three groups: RYGB (n = 11), sham surgery 
and body weight matched with RYGB (Sham- 
BWM, n = 5), and sham surgery with food ad 
libitum (Sham-obese, n = 5) (Figure 1a). Urine 
and feces were collected at pre-surgery, 1, 2, and 
4 weeks post-surgery. Plasma samples including 
both portal vein and peripheral blood were col-
lected at week 4.
Within 6 days of intervention, mean body 
weights of RYGB and Sham-BWM rats were 
significantly reduced compared to pre- 
intervention, reaching a plateau (~430 g) over the 
remaining period of the study (Figure 1b). Mean 
body weight of Sham-obese rats was significantly 
higher than that of either RYGB or Sham-BWM 
groups from 6 days post-surgery onwards (Figure 
1b). While Sham-obese rats consumed 
a significantly higher amount of food than RYGB 
and Sham-BWM groups, the food intake of RYGB 
and Sham-BWM were similar despite the different 
weight loss strategies (Figure 1c). An oral glucose 
tolerance test (OGTT) showed significantly lower 
concentrations of plasma glucose in the RYGB 
group compared with Sham-obese (p = .0005) or 
Sham-BWM (p = .0008) groups at 60 mins follow-
ing an oral dose of glucose, while sham-BWM 
exhibited significantly lower levels than the Sham- 
obese group (p = .048) (Figure 1d). The area under 
the curve (AUC) of the glucose concentrations over 
120 min of OGTT was significantly lower in RYGB- 
operated rats than in Sham-obese rats (Figure 1e). 
Consistent with their insulin resistance, Sham- 
obese rats had the highest insulin levels among 
the three groups during the OGTT (Figures 1e 
and 1f).
RYGB alters fecal bacterial composition
There was no significant difference in Shannon 
diversity index, species richness, or Chao1 between 
RYGB and Sham-obese or Sham-BWM, except for 
a significantly higher Shannon diversity index in 
Sham-BWM compared to the other two groups at 
week 4 (Fig S1). These alpha diversity measure-
ments were not significantly different between 
time points within each experimental group. 
While all the animals had a similar starting micro-
biota, RYGB rats experienced deviation at a larger 
scale over time, whereas Sham-obese remained 
tightly clustered and Sham-BWM showed 
a temporary diversification at week 1 before retro-
ceding to the same multivariate space occupied by 
pre-surgery samples (Figure 2a, Fig S2A). Bacterial 
families such as Lactobacillaceae and 
Peptostreptococcaceae were reduced post-RYGB 
surgery but not in the Sham groups (Figure 2b). 
In the Sham-BWM group, the relative abundance 
of Coriobacteriaceae and Lachnospiraceae were sig-
nificantly changed at week 1 and shifted back to 
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pre-intervention level (Figure 2c-2d). In contrast, 
Coriobacteriaceae and Enterococcaceae were 
consistently increased, whereas Lactobacillaceae, 
Peptostreptococcaceae, Ruminococcaceae were 
reduced post-RYGB (Figure 2e-2i). 
Streptococcaceae increased at 1-week post-RYGB 
and shifted back to pre-surgery level by week 4 
(Figure 2j).
Figure 1. Impact of the Roux-en-Y gastric bypass surgery on phenotypic changes of Zucker obese rats. Experimental design, sample collection 
and analyses (a); animal body weight (b) and food intake (c) throughout the experimental period; following an oral glucose tolerance 
test, plasma concentrations of glucose (d) and insulin (f), and the areas under the curves (AUCs) for glucose and insulin (e, g). Data are 
shown as mean±SEM and statistical differences were determined by two-way ANOVA with Tukey’s multiple comparisons test (b, c, d & 
f), whereas Kruskal-Wallis test was used to determine the significance level of the AUCs among the RYGB (blue), sham-obese (red) and 
sham-BWM (green) groups. Dunn’s multiple comparisons test was used for pairwise comparisons of the AUCs between any of the two 
groups. * indicates statistically significant differences between RYGB and Sham-BWM (* p < .05; ** p < .01; *** p < .001). ^ indicates 
statistically significant differences between RYGB and Sham-obese (^ p < .05; ^^ p < .01; ^^^ p < .001). # indicates statistically significant 
differences between Sham-BWM and Sham-obese (# p < .05; ## p < .01; ### p < .001). a indicates statistically significant differences 
between post surgical time points and pre-surgery of the same intervention group (a p < .05; aa p < .01; aaa p < .001).
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We did not observe any significant changes among 
the groups at pre-surgery, nor between Sham-obese 
and Sham-BWM at any time point. However, the 
RYGB group showed significantly lower abundances 
of Peptostreptococcaceae at week 1 and unclassified 
Clostridiales, Ruminococcaceae and Lachnospiraceae 
at week 4, while there was a higher abundance of 
Enterococcaceae at week 1 compared with Sham- 
BWM (Fig S2B). When comparing Sham-obese to 
RYGB, higher levels of Erysipelotrichaceae and lower 
levels of Lactobacillaceae were observed at both week 
1 and 4 in RYGB animals. Furthermore, 
Peptostreptococcaceae, Clostridiaceae, and unclassified 
Clostridiales were found to be underrepresented in 
RYGB versus Sham-obese, whereas Coriobacteriaceae 
were overrepresented.
RYGB-induced weight loss-independent global 
metabolic changes in feces over time
To investigate the impact of RYGB on fecal meta-
bolite composition, we used 1H NMR spectroscopy 
to analyze fecal water extracts from RYGB, Sham- 
BWM, and Sham-obese groups at pre- and 1-, 2- 
Figure 2. Impact of the Roux-en-Y gastric bypass surgery on fecal microbial profiles of Zucker obese rats. A NMDS plot (a) and 
a heatmap (b) of fecal family-level taxonomic profiles from RYGB, sham-obese and sham-BWM groups at pre-surgery (Pre), and 1- 
(1 wk) and 4-weeks (4 wk) post-surgery. Clustering analysis was based on the Pearson correlation coefficient as the distance measure 
between data points and the average linkage as clustering algorithm. Box plots show significantly changed bacterial families including 
Coriobacteriaceae (c) and Lachnospiraceae (d) in sham-BWM group and Coriobacteriaceae (e), Enterococcaceae (f), Lactobacillaceae (g), 
Peptostreptococcaceae (h), Ruminocoaccaceae (i), and Streptococcaceae (j) in RYGB group across three measured time points. Kruskal- 
Wallis H-test and Tukey-Kramer post-hoc test were used and Benjamini-Hochberg FDR was used for multiple test correction.
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and 4-week post-surgery and a PCA scores plot 
showed a sustained impact of RYGB surgery at 
4 weeks compared to transient effects of the sham- 
operated animals (Fig S3A). A more detailed tem-
poral analysis using PCA trajectory plots, calculated 
from the PCA scores plots, showed that prior to 
RYGB or sham surgery, all animals had similar 
baseline fecal metabolomes, which started to devi-
ate as early as 1-week post intervention (Figure 3a). 
The RYGB group showed a greater metabolic shift 
from pre-surgery to post-surgery time points along 
both the first and second principal components 
(PC1 and PC2). In contrast, the Sham-BWM and 
Sham-obese groups deviated along PC1 (Figure 3a). 
PCA and O-PLS-DA analyses were subsequently 
carried out to specifically investigate (1) caloric 
restriction-induced metabolic changes by compar-
ing the Sham-BWM with the Sham-obese group; 
Figure 3. Impact of the Roux-en-Y gastric bypass surgery on fecal and urinary metabolic profiles of Zucker obese rats. PCA trajectory 
scores plots of fecal water (a) and urine (c) based on 1H NMR spectral data obtained from RYGB (blue), sham-BWM (green) and sham- 
obese (red) Zucker rats at pre-surgery (square), 1- (triangle), 2- (diamond) and 4-week (circle) post-surgery. Each dot represents the 
average scores of the first principal component (PC1) against the second principal component (PC2) from each group. Error bars are 
expressed by the standard error of the mean of PC1 and PC2 at each time point. Heatmaps of significantly changed metabolites 
between RYGB and Sham-obese (OvsR) or Sham-BWM (BvsR) in feces (b) and urine (d) at each time points (1, 2 and 4 weeks). 
Correlation coefficient (r) shown in the heatmaps were obtained from OPLS-DA models. Positive (red) or negative (blue) r values 
indicate higher or lower concentrations of the metabolites in RYGB compared with either of the sham groups. *, +, # and ^ indicate 
significant levels of metabolite differences between pairwise groups at each time point at p < .05, p < .01, p < .001 and p < .0001, 
respectively using two-tailed heteroscedastic t-test with Benjamini-Hochberg correction. Keys: 3-HPPA, 3-Hydroxyphenylpropionate; 
GABA, γ-amino-butyric acid.
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(2) RYGB-induced metabolic changes by compar-
ing the RYGB with the Sham-obese group; and (3) 
RYGB-induced body weight-independent meta-
bolic changes by comparing the RYGB with the 
Sham-BWM group. There were no significant 
metabolic differences in fecal water among the 
three groups of animals at pre-surgery. Given that 
caloric restriction-induced significant body weight 
loss, we did not observe any significant metabolic 
changes in feces between Sham-BWM and Sham- 
obese groups (Table S1). However, significant 
metabolic differences between RYGB and either of 
the Sham groups were observed at post-surgery 
time points (Figs S4-S5). A heatmap (Figure 3b) 
demonstrates significant metabolic differences 
between RYGB and Sham-obese or Sham-BWM. 
RYGB-operated rats showed higher fecal levels of 
γ-amino butyric acid (GABA), and lower levels of 
succinate, N-acetylglucosamine, cytosine, methyl-
malonate and tyrosine over the 4-week postopera-
tive period compared with Sham-BWM or Sham- 
obese. In contrast, short chain fatty acids (SCFAs), 
such as formate and propionate, lactate and 
3-hydroxyphenylpropionate (3-HPPA) were lower 
throughout the post-surgery period in the RYGB 
than in the Sham-obese group, whereas these meta-
bolite changes were only observed at one or two 
time points in the comparison between Sham- 
BWM and RYGB groups. While trimethylamine 
was higher in RYGB compared to Sham groups at 
week 1 and 2 post-op, SCFAs including acetate, 
valerate and butyrate were lower at later time 
points. Notably, a smaller number of changed 
metabolites between RYGB and Sham-BWM at 
week 1 was observed in contrast to the other com-
parisons, suggesting that caloric restriction induced 
an initial but temporary metabolic disturbance. 
These observations suggested that body weight 
reduction through caloric restriction and RYGB 
manifest different metabolic patterns.
RYGB induces weight loss-independent global 
metabolic changes in urine over time
Urinary profiles of the Sham-BWM group pre-
sented a tight clustering of all time points, while 
Sham-obese and RYGB groups shifted dramati-
cally, forming three distinctive clusters represent-
ing each experimental group (Figure 3c and S3B). 
There was no significant difference in the urinary 
profiles between Sham-BWM and Sham-obese at 
any time points (Table S1). In contrast, metabolic 
differentiation RYGB and Sham-obese or Sham- 
BWM was observed over all post-surgical time 
points (Figs S6-S7). The concentrations of TCA 
cycle intermediates (e.g., citrate, 2-oxoglutarate, 
succinate, fumarate and malate) were lower in 
RYGB compared with Sham groups, whereas the 
host-microbial co-metabolites including indoxyl 
sulfate (IS), 4-hydroxyphenylacetate, 4-cresyl glu-
curonide and phenylacetylglycine (PAG) were 
higher (Figure 3d). Urinary levels of 2-oxoisovale-
rate, the breakdown products of branched chain 
amino acid (BCAA), valine, were found to be 
higher in RYGB than in Sham animals. However, 
3-methyl-2-oxovalerate, a breakdown product of 
isoleucine, was lower in RYGB compared to Sham- 
obese. Furthermore, Nε-acetyllysine, 
N-acetylalanine and Nα-acetyllysine were found to 
be lower in RYGB.
RYGB affects biochemical composition of 
peripheral and portal vein blood plasma
Portal vein vs. peripheral plasma: The PCA scores 
plot of the peripheral and portal vein plasma from 
all three groups showed a clear clustering based on 
experimental groups (Figure 4a-4c). RYGB animals 
were separated from the Sham animals along PC2, 
whereas Sham-BWM and Sham-obese appeared to 
group along PC1. While neither Sham-BWM nor 
Sham-obese demonstrated differences between 
portal vein and peripheral plasma (Table S1), the 
RYGB group showed higher levels of N,N, 
N-trimethyllysine, propionate, formate, and succi-
nate in the portal vein than in peripheral plasma 
(Figure 4d). Acetate levels were also high but did 
not reach a statistical significance post Benjamini- 
Hochberg (BH) correction (p = .06).
RYGB vs Sham groups: Regardless of peripheral 
or portal vein plasma, the two Sham groups exhib-
ited no significant differences (Table S1). However, 
RYGB rats showed significantly lower levels of 
BCAA (i.e. leucine, isoleucine and valine) and 
higher levels of pyruvate in contrast to Sham 
groups (Figure 4d). Furthermore, portal vein 
blood levels of choline, phenylalanine, glycerol, 
glycerophosphorylcholine and propionate were 
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lower in RYGB compared with the Sham-BWM. 
Portal vein blood levels of tyrosine was lower in 
RYGB compared to Sham-obese but did not reach 
statistical significance post BH correction (p = .06).
RYGB significantly alters bile acid composition 
in portal vein and peripheral plasma but not in 
urine
BAs released during digestion are re-absorbed back 
to the liver from the distal ileum through the enter-
ohepatic circulation. Therefore, BA profiles of the 
portal vein blood reflect the ileal re-absorption, 
whereas that of peripheral blood and urine repre-
sent the circulating and excreted BAs, respectively. 
We did not observe significant BA differences 
between RYGB and Sham groups after applying 
multiple testing corrections.
Portal vein vs. Peripheral plasma: We identified 32 
bile acids in plasma samples using a UPLC-MS- 
based bile acid profiling method (Table S2). A total 
of 7, 11, and 3 bile acids were significantly higher in 
the portal vein compared to peripheral plasma in 
Sham-obese, Sham-BWM and RYGB groups, 
respectively (Figure 5a-5c). Caloric restriction had 
a more profound impact on bile acids than RYGB 
Figure 4. Impact of the Roux-en-Y gastric bypass surgery on portal vein and peripheral plasma metabolic profiles of Zucker obese rats. 
PCA scores plots (a, b, c) of 1H NMR spectral data obtained from peripheral (dot) and portal vein (triangle) samples from RYGB (blue), 
sham-BWM (green) and sham-obese (red) Zucker rats at 4-week post-operation. A heatmap (d) of significantly changed metabolites 
between RYGB and Sham-obese or Sham-BWM in systemic (s) and portal vein blood plasma (p). Correlation coefficient (r) shown in the 
heatmap were obtained from OPLS-DA models. Positive (red) or negative (blue) correlation coefficient values indicate higher or lower 
concentrations of the metabolites in RYGB or RYGB portal vein compared with either of the sham groups or RYGB peripheral plasma. *, 
+ and # indicate significant levels of metabolite differences between the groups at p < .05, p < .01 and p < .001, respectively, using 
two-tailed heteroscedastic t-test with Benjamini-Hochberg correction. a Metabolites with a p = .06 post BH correction.
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did. RYGB disturbed bile acid circulation and meta-
bolism, resulting in a more similar bile acid compo-
sition between the peripheral and portal vein plasma. 
3α-hydroxy-12 ketolithocholic acid, taurocheno-
deoxycholic acid and tauro-β muricholic acid, were 
found to be higher in the portal vein compared to 
peripheral plasma in both RYGB and Sham-BWM, 
but not in the Sham-obese group. Furthermore, 
higher levels of deoxycholic acid, tauro-α muricholic 
acid, tauro-ursocholanic acid, and tauro- 
ursodeoxycholic acid were observed in portal vein 
compared to systemic levels in both Sham groups.
RYGB vs. Sham groups: The levels of bile acids in 
the RYGB group were lower than those in the Sham 
groups. The RYGB group showed lower levels 
of primary bile acids (e.g., cholic acid, 
chenodeoxycholic acid and α-muricholic acid) 
and secondary bile acids (e.g., hyodeoxycholic 
acid and 3α-hydroxy-7 ketolithocholic acid) com-
pared with Sham-obese in the portal vein plasma 
(Figure 5d). Taurohyodeoxycholic acid and tauro-
chenodeoxycholic acid were significantly lower in 
RYGB compared to Sham-BWM (Figure 5d). 
Unlike in portal vein plasma, levels of only 4 BAs 
were altered in peripheral plasma between RYGB 
and Sham-obese. These include taurine-conjugated 
BAs, such as taurochenodeoxycholic acid and taur-
ohyodeoxycholic acid, as well as the unconjugated 
chenodeoxycholic acid, and hyodeoxycholic acid 
(Figure 5e). While similar trends of these changes 
were observed between RYGB and Sham-BWM 
groups, no statistical significance was achieved.
Figure 5. Impact of the Roux-en-Y gastric bypass surgery on portal vein and peripheral plasma bile acids of Zucker obese rats. Bile acids 
that significantly differed between portal vein and peripheral plasma in sham-obese (a), sham-BWM (b) and RYGB (c) groups, and bile 
acids that significantly differed between RYGB and sham-obese or sham-BWM (p < .05 by multiple t-test with FDR correction) in portal 
vein (d) and in peripheral plasma (e). Bars are presented by mean±SD. * indicates statistically significant differences between 
peripheral and portal vein plasma or between RYGB and Sham-BWM (* p < .05; ** p < .01; *** p < .001). ^ indicates statistically 
significant differences between RYGB and Sham-obese (^ p < .05; ^^ p < .01; ^^^ p < .001).
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Discussion
RYGB surgery induced a range of metabolic 
changes over a 4-week period post-surgery inde-
pendent of weight loss through caloric restriction 
(Figure 6). The levels of bacterial metabolites, such 
as urinary indoxyl sulfate, and fecal succinate, tyr-
osine and GABA, changed as early as the first post- 
surgical time point (i.e., 1-week post-op) and these 
changes differentiating the RYGB from the Sham 
groups were consistent across the 4-week study 
period. However, other host-bacterial co- 
metabolites including PAG and 4-cresyl glucuro-
nide were found to be significantly different 
between the RYGB and the sham groups only at 
later time points (i.e., 2- and 4-week post-op). 
SCFA production through bacterial fermentation 
of dietary fiber was significantly altered. Fecal levels 
of SCFAs such as formate, acetate, and propionate 
were consistently lower in RYGB group compared 
to Sham-obese at all post-surgical time points. 
However, in contrast to Sham-BWM, these changes 
were observed in RYGB group at later time points 
(i.e. 2 and 4 weeks), suggesting that caloric restric-
tion may partially contribute to these reduced 
SCFAs. Caloric restriction has been reported to 
reduce total cecal SCFA levels14 and microbial 
butyrogenesis and acetogenesis in rats.15 This 
observation is consistent with the reduced relative 
cecal acetate in RYGB-operated mice compared to 
both Sham-obese and Sham-BWM mice previously 
reported, although butyrate was reported to be 
unchanged and propionate increased.16 Our obser-
vations suggested a reduced bacterial activity of 
fiber fermentation post-RYGB, which is likely due 
to reduced bioavailability of fiber in the colon and/ 
or shifted bacterial composition. However, in this 
study, Sham-BWM and RYGB groups had similar 
food intake and therefore, the reduced SCFA levels 
in feces are likely to due to the bacterial composi-
tional changes. This fact agrees with our observa-
tion that bacterial families, Ruminococcaceae and 
Lactobacillaceae, were found to be significantly 
reduced post RYGB, together with a trend towards 
lower abundance of Lachnospiraceae, which was 
not statistically significant. Bacteria from these 
families have been reported to produce SCFAs, for 
example, Faecalibacterium prausnitzii and 
Subdoligranulum variabile from Ruminococcaceae, 
Roseburia inulinivorans, and Eubacterium rectale 
from Lachnospiraceae, and Lactobacillus reuteri 
from Lactobacillaceae.17 Butyrate is the primary 
Figure 6. Schematic illustration of systemic changes observed in biofluids from RYGB-operated obese rats compared to Sham-BWM. 
Red indicates higher relative concentration, whereas blue indicates lower relative concentration of metabolites in RYGB compared with 
Sham-BWM. Key: GABA, γ-amino butyric acid; PEP, phosphoenolpyruvate; TCA cycle, tricarboxylic acid cycle; TCDCA, taurochenodeoxy-
cholic aicd; THDCA, taurohyodeoxycholic acid.
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energy source of colonocytes18 and its decreased 
availability in feces may indicate an increase in 
other energy generation pathways, such as glycoly-
sis or β-oxidation to compensate for the energy 
demands. A study on antibiotic-induced micro-
biome depletion demonstrated a shift in energy 
metabolism from SCFAs to glycolysis in entero-
cytes, affecting glucose homeostasis.18 Butyrate is 
believed to be a protective metabolite in the gut, 
implicates in the maintenance of gut integrity and 
has an anti-inflammatory role;19 therefore, its 
decrease may result in a reduction of these bene-
ficial effects post RYGB. Moreover, a significantly 
higher levels of propionate in the portal vein blood 
was observed in Sham-BWM but not in Sham- 
obese compared to RYGB rats. Notably, fecal 
propionate was higher in Sham-obese across 
4 weeks but not in Sham-BWM compared to 
RYGB. These findings together suggested that calo-
ric restriction could result in a higher uptake of 
propionate via portal vein blood. It has been 
shown that 6-week caloric restriction in rats pro-
moted the expression of microbial enzymes 
involved in propionogenesis.15 Propionate has 
been shown to reduce hepatic and serum fatty 
acid levels, the elevated levels of which can cause 
inflammation.20 Propionate may indirectly contri-
bute to improved insulin sensitivity since both ele-
vated-free fatty acids and inflammation can result 
in insulin resistance.20 This observation is consis-
tent with our phenotypic data from the Sham- 
BWM animals, exhibiting similar insulin and 
glucose concentrations as compared to RYGB 
group following an oral glucose tolerance test. 
Propionate can also impact on food intake through 
GPR signaling, inducing the release of satiety hor-
mones such as GLP-1 and PYY,21 as well as con-
trolling energy expenditure by GPR41 signaling.22 
Our data indicated that caloric restriction increased 
absorption of propionate, which in turn could 
potentially impact on food intake, forming 
a positive feedback loop.
Levels of microbially-derived neuroactive inter-
mediate, GABA, were higher in RYGB-operated 
animals compared to Sham groups, which is in 
agreement with previous studies on rodent models 
of RYGB.6 Bacterial genera, such as Enterococcus, 
Bacteroides, Escherichia, and Klebsiella, have been 
reported to be involved in GABA biosynthesis.23 
We observed that Enterococcus spp. was present in 
higher abundance post-RYGB. In addition, GABA 
has been reported to regulate gut motility24 and 
may affect food transition in the gut post-RYGB. 
GABA also stimulates release of GLP-1, which reg-
ulates glucose homeostasis by improving insulin 
secretion, from enterocytes through ionotropic 
GABAA and GABAC receptors.25 The increase in 
GLP-1, which is consistently observed in patients 
and animals post RYGB surgery,3 can in turn pro-
mote GABA production from pancreatic β-cells, 
creating a loop maintaining fecal and plasma 
GABA levels.6 We observed that RYGB animals 
exhibited improved insulin levels and glucose tol-
erance compared to Sham-obese, suggesting that 
microbially-derived GABA may play a role in sur-
gery-induced metabolic benefits.
Aromatic amino acids (e.g., phenylalanine and 
tyrosine) and their metabolites were altered by 
RYGB surgery in obese Zucker rats. We found 
lower fecal levels of tyrosine and 3-HPPA, together 
with higher levels of urinary 4-cresyl glucuronide, 
4-hydroxyphenylacetate, indoxyl sulfate, and PAG 
in RYGB-operated animals compared to Sham 
groups. In portal vein plasma, the uptake of phe-
nylalanine and tyrosine was reduced in RYGB com-
pared to Sham groups. These observations 
collectively led us to conclude that the absorption 
of aromatic amino acids was reduced post-RYGB 
and their bioavailability in the colon is likely to 
increase, allowing the gut bacteria to produce p-cre-
sol and phenylacetate from tyrosine and phenylala-
nine, respectively. Consistent with the findings in 
a recent study by Haange et al.5 the concentrations 
of aromatic amino acids were reported to be lower 
in the cecum and colon content following RYGB, 
whereas the amines such as dopamine and 
histamine formed by Proteobacteria via decarbox-
ylation of the corresponding precursor amino acids 
were higher. P-cresol and phenylacetate were sub-
sequently taken into the liver for conjugation with 
glucuronide or glycine to form 4-cresyl glucuronide 
and PAG, respectively. 3-HPPA is a bacterial meta-
bolite formed from phenylalanine. Our finding sug-
gested that RYGB could facilitate greater 
conversion of phenylalanine to phenylacetate than 
to 3-HPPA. High indoxyl sulfate levels may lead to 
adverse effects on kidney and heart function since it 
is a uremic toxin associated with atherosclerosis.26 
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However, this metabolic observation conflicts with 
the clinical observation of improved heart function 
post-bariatric surgery. Increased aromatic amino 
acid metabolism by the gut microbiota may indi-
cate potential harmful effects of RYGB in the long 
term since a meta-analysis on functional microbial 
signatures in colorectal cancer displayed an enrich-
ment in amino acid degradation pathways.27 In 
addition, bacterial choline metabolism was 
enhanced by RYGB surgery, reflected by higher 
fecal trimethylamine, a bacterial product of choline 
and lower absorption of choline through the hepa-
tic portal vein in the RYGB compared to Sham 
groups. Metagenomic analysis of colorectal cancer 
datasets further showed choline trimethylamine- 
lyase gene was overabundant in colorectal cancer 
patients.28 Moreover, there is evidence that baria-
tric surgery could increase the risk of colon cancer 
development in the long-term.29,30
The fecal bacterial composition was temporarily 
affected by caloric restriction with a higher abun-
dance of Coriobacteriaceae and a lower abundance 
of Lachnospiraceae at week 1 compared to pre- 
intervention and these changes normalized by 
week 4. Low abundances of Lachnospiraceae were 
consistent with the previously reported taxa that 
are associated with caloric restriction.31 While calo-
ric restriction has been reported to induce changes 
in levels of amino acids, ketone bodies, bile acids, 
and host-microbial co-metabolites,31 we did not 
observe significant differences in the metabolic pro-
files between Sham-obese and Sham-BWM using 
multivariate statistical analysis methods. This result 
could be owing to a relatively short period of caloric 
restriction (4 weeks) and/or a small group size of 
the sham groups. The abundance of 
Coriobacteriaceae was found to be significantly 
increased following RYGB, which corroborates 
a recent report on diabetic rats post-RYGB.32 
Coriobacteriaceae statistically and negatively corre-
lated with hepatic glucose and glycogen in germ- 
free mice exposed to a conventional environment, 
suggesting a potential impact of Coriobacteriaceae 
on glucose metabolism. In the current study, given 
that Sham-BWM and RYGB rats exhibited a similar 
body weight loss, the relative abundances of fecal 
bacterial families such as Peptostreptococcaceae, 
Ruminococcaceae, and Lachnospiraceae were 
found to be higher in Sham-BWM compared to 
RYGB, suggesting that caloric restriction- and 
RYGB-induced weight loss could be associated 
with different bacteria. This is supported by 
a pilot study comparing the fecal bacterial compo-
sition of patients who underwent medical weight 
loss (MWL), adjustable gastric banding (AGB), or 
RYGB.33 With a similar weight loss and glycemic 
improvement, the study showed that RYGB 
induced the most number of bacterial species shifts 
compared to the other two groups and alpha- 
diversity was significantly lower in AGB compared 
to RYGB and MWL.33 Consistently, in a diabetic rat 
model, RYGB and sleeve gastrectomy induced simi-
lar glucose improvement but produced distinct 
fecal bacterial signatures.34 Another study based 
on fecal microbiota transplantation showed that 
mice receiving the fecal microbiota from patients 
with poor weight loss post-RYGB exhibited 
a greater weight gain compared to those who were 
transplanted with the microbiota from the success-
ful responders.35 While no statistical differences in 
the fecal microbial composition were found 
between poor and successful weight loss respon-
ders, Barnesiella was observed to be associated 
with weight gain in the recipient mice.35 
Furthermore, de Jonge et al. showed that nonsurgi-
cal duodenal–jejunal bypass liner, which excludes 
the proximal 60 cm small intestine from food, 
induced an increased fecal abundance of 
Proteobacteria, but that this shift reverted to base-
line levels after removal of the liner, while the 
weight loss persisted.36 These observations sug-
gested that these fecal microbial shifts are likely to 
be independent of weight loss.
Bile acids are believed to play a key role in 
achieving metabolic benefits of RYGB surgery.37 
However, while the majority of studies in animal 
models and patients have shown a surge in plasma 
BA levels postoperatively,38,39 others reported no 
change40 or even a reduction.41 Similarly, fecal bile 
acids have been shown to markedly decrease in 
patients and rats after RYGB,6,42,43 raising the ques-
tion of the role of luminal bile acids in regulating 
metabolic function. In this study, we showed that 
BA levels in portal vein were higher compared to 
peripheral blood in all three groups of animals, with 
the highest number of disturbed BAs in Sham- 
BWM, suggesting caloric restriction has a greater 
impact on BA composition. Three BAs, namely, 3α- 
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hydroxy-12-ketolithocholic acid, taurocheno-
deoxycholic acid, and tauro-β-muricholic acid 
were found to be higher in portal vein blood in 
both RYGB and Sham-BWM groups compared to 
their systemic levels, which could be due to reduced 
food intake following the surgery. Moreover, pri-
mary BAs such as cholic acid and chenodeoxy-
cholic acid, and secondary BAs, mainly taurine- 
conjugated BAs (e.g., taurohyodeoxycholic acid 
and taurochenodeoxycholic acid) were present at 
lower levels in RYGB compared to Sham-operated 
groups, which is consistent with the observations in 
a mini-pig model post-RYGB.44 Notably, ileal con-
jugated bile acids are also lower in RYGB-operated 
compared to Sham-obese rats,45 suggesting that 
their increased deconjugation by ileal microbiota 
account for their decreased reabsorption into the 
enterohepatic circulation. Simonen and 
colleagues39 showed that despite total serum BA 
levels increasing post RYGB, levels of conjugated 
BAs, specifically taurine-conjugated BAs, decreased 
and this change was associated with increased lipid 
oxidation at the expense of glucose oxidation. This 
data corroborates our observations of reduced 
plasma lipids and glycerophosphorylcholine. FXR 
signaling, mainly activated by chenodeoxycholic 
acid, modulates BA synthesis, lipid metabolism, 
glucose homeostasis, and inflammation.46 Taurine- 
conjugated BAs are the most potent activators of 
TGR5 receptor.46 TGR5 signaling is implicated in 
energy balance, GLP-1 secretion, glucose metabo-
lism and insulin sensitivity.11,47 However, the 
reduction of plasma BA levels observed in our 
study may suggest that the axis of BAs and TGR5/ 
FXR signaling may not be the key mechanism, 
through which RYGB improves glucose tolerance 
and insulin sensitivity in Zucker obese rats, which 
is in agreement with a previous study carried out 
using TGR5-/- mice.48 A growing body of evidence 
suggests that temporal changes in BA levels could 
be unrelated to glycemic control early after gastric 
bypass.49 Furthermore, disruption of enterohepatic 
circulation using BA sequestrants50 or inhibitors of 
BA transporters51 resulting in reduced plasma BAs 
and increased fecal excretion nonetheless improved 
glucose metabolism.
An increase in TCA cycle activity post-RYGB 
was observed, as reflected by decreased urinary 
levels of TCA cycle intermediates and increased 
plasma levels of pyruvate, which are consistent 
with previous findings.6,52 Furthermore, it was 
noted that these intermediates apart from succinate 
were not significantly changed between Sham- 
BWM and RYGB until week 2 post-intervention, 
indicating that caloric restriction increased TCA 
cycle activity temporarily, whereas RYGB exerted 
a more sustained effect on TCA cycle. The high 
pyruvate level we observed in both portal vein and 
peripheral plasma after RYGB denotes augmented 
glycolysis and inhibition of gluconeogenesis. 
Another study on RYGB-operated rodents has 
reported increased glucose uptake and utilization 
in the Roux limb of the intestine.53 Therefore, sti-
mulated glycolysis and resulting increased TCA 
cycle flux could contribute to increased energy 
expenditure post-RYGB.
Systemic metabolic profiles of obese Zucker rats 
collectively demonstrated that RYGB surgery 
reduced bacterial fermentation activities of fiber, 
and increased choline and host-microbial co- 
metabolisms, which are weight loss independent. 
For the first time, we studied the biochemical com-
position of both peripheral and portal vein plasma 
post-RYGB surgery and found reduced absorption 
of choline, aromatic amino acids and SCFAs, as 
a result of anatomic alteration of the intestine and 
bacterial compositional and functional changes. 
These findings provide a valuable resource for 
how dynamic, multi-systems changes impact on 
overall metabolic health, and may provide potential 
therapeutic targets for developing downstream 
non-surgical treatment for metabolic disease.
Materials and methods
Animals and experimental design
All experiments were approved by the Veterinary 
Office of the Government of Unterfranken, 
Germany (License 55.2–2531.01-72/12). Twenty- 
one male Zucker fa/fa rats at 6 weeks of age with 
a mean body weight of 327 ± 18 g were purchased 
from Charles River (France). Male rats were used 
to avoid confounders introduced by the estrous 
cycle since it has been shown that estradiol- 
treated ovariectomized rats exhibited a higher 
weight loss post-RYGB compared to non-treated 
control rats.54 Animals were individually housed 
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under ambient humidity and temperature for 22° 
C in a 12 h light/dark cycle. Animals had free 
access to tap water and Purina 5008 Lab diet 
(Purina Mills, USA, 16.7% of calories from fat) 
unless stated otherwise. At 12 weeks of age, 11 
rats were subjected to RYGB surgery and the 
other 10 were undergone sham surgery. After sur-
gery, RYGB (n = 11) and sham-operated (n = 5, 
Sham-obese) rats were fed ad libitum. The other 
five sham-operated rats were calorie restricted and 
received the amount of calories necessary to 
achieve the same body weight as the RYGB 
group (Sham-BWM). The group size was deter-
mined based on previous studies.55,56 The study 
design is shown in Figure 1a. Food intake and 
body weight were measured daily. As regulation 
of glucose control and the secretion of the gastro-
intestinal peptide hormones are under circadian 
rhythm,57 we measured food intake every 2 hours 
in Sham-obese and RYGB rats. Based on these 
results, 33% of the daily food intake of Sham- 
obese rats was fed to Sham-BWM rats during the 
light phase, and 66% at the beginning of the dark 
phase. We performed all metabolic measurements 
at the beginning of the dark phase to avoid possi-
ble confounders related to the circadian rhythm.
Surgery and perioperative care
Rats were food deprived for 6 h pre-operatively. 
Surgical anesthesia was induced and maintained 
with isoflurane/O2 mixture. Animals were placed on 
a heating pad during surgery. Prior to surgery animals 
were given 5 mg/kg carprofen subcutaneously. The 
abdomen was opened using a midline laparotomy 
and closed using continuous suturing. Sham surgery: 
The small bowel and gastro-esophageal junction were 
mobilized and a gastrostomy on the anterior wall of 
the stomach and a jejunostomy with subsequent clo-
sure were performed. Eleven rats underwent sham 
surgery and were included in the study. RYGB 
surgery: Surgery was performed according to 
a standardized protocol which has been shown to 
result in weight loss and its long-term maintenance. 
Briefly, the jejunum was transected 16 cm aboral to 
the pylorus to create the biliopancreatic limb. The 
stomach was divided 3 mm below the gastro- 
esophageal junction to create a small pouch. The 
stomach remnant was subsequently closed. The 
aboral jejunum was anastomosed end-to-side to the 
small pouch. At the level of the lower jejunum, 
a 7 mm side-to-side jejuno-jejunostomy between the 
biliopancreatic limb and the alimentary limb was 
performed creating a common channel of ~25 cm 
in length.
Measurement of oral glucose tolerance, glucose 
and fasting insulin
An oral glucose tolerance test (OGTT) was per-
formed at the beginning of the dark cycle in all 
animals 2 days prior to the biofluid sample collec-
tion at week 4 post-operation. In order to avoid oral 
gavage and therefore to reduce discomfort and 
pressure on the upper anastomosis, animals were 
trained to drink 10 ml/kg body weight of a 25% 
glucose solution within 10 min after an overnight 
fast on two occasions before the OGTT was per-
formed. After an 8-h overnight fast, blood glucose 
was measured (Breeze 2® glucometer, Bayer, 
Zurich, Switzerland) in conscious rats at baseline, 
and 15, 30, 60, and 120 minutes after glucose inges-
tion. Blood was obtained from the tail vein by 
a small incision. A drop of blood was applied 
directly to a glucometer and 100 µl were collected 
at each time point in tubes containing EDTA and 
a dipeptidyl peptidase-4 inhibitor for insulin mea-
surement. The plasma fraction was separated by 
centrifugation at 4°C, 8000 rpm and stored at 
−80°C. Total insulin was measured using the 
Ultrasensitive Rat Insulin ELISA (Merodia AB, 
Sweden 10–1251-10).
Sample collection
Urine and feces were collected prior to the surgery 
(pre-op) and 1, 2, and 4 weeks post-surgery using 
metabolic cages (Techniplast, 3701M081) during 
the dark phase. Animals were provided with free 
access to water and diet. At the sacrifice time point, 
hepatic portal vein and peripheral blood were col-
lected, and plasma samples were obtained from 
each animal.
NMR spectroscopic analysis
Approximately 250 mg of homogenized fecal sam-
ples were mixed with 500 μL HPLC-grade water in 
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1.5 mL microtubes. The mixtures were sonicated 
for 3 × 10 minutes at 25°C and vortexed when each 
sonication cycle was completed. The mixtures were 
centrifuged at 16,000 x g for 10 min at 4°C and the 
supernatant was collected for subsequent 1H NMR 
spectroscopic analysis. A total of 400 μL fecal water 
extract or urine was transferred into a clean 1.5 mL 
microtubes and mixed with 250 μL of 0.2 M sodium 
phosphate buffer (100% D2O, 0.01% TSP (3-(tri-
methylsilyl)propionic-2,2,3,3-d4 acid sodium salt) 
as a chemical shift reference, and 3 mM sodium 
azide (NaN3) as a bacteriostatic reagent, pH 7.4). 
The mixture was vortexed and centrifuged at 
16,000 x g for 10 min at 4°C and 600 μL of super-
natant was transferred into NMR tube with an 
outer diameter of 5 mm.
1H NMR spectra of all fecal samples were acquired 
using a 600 MHz spectrometer (Bruker Avance III, 
Bruker Biospin, Germany) with 5 mm broadband 
inverse configuration probe with a z axis magnetic 
field-gradient capability operating at 600.13 MHz for 
proton. D2O in the sodium phosphate buffer was 
used to lock the magnetic field. A standard 1-dimen-
sional (1-D) NMR pulse [recycle delay (RD)-90°-t1 
-90°-tm-90°-acquire free induction decay (FID)] was 
employed at 300 K for the acquisition of fecal water 
spectra. A total of 128 scans were recorded into 64 
k data points with a spectral width of 20 ppm.
Urine samples were prepared by combining 
400 μL of urine with 250 μL of 0.2 M sodium 
phosphate buffer (100% D2O, 0.01% TSP, and 
3 mM sodium azide (NaN3), pH 7.4). The mixture 
was vortexed and centrifuged at 16,000 x g for 
10 min at 4°C and 600 μL of supernatant was 
transferred into NMR tube with an outer diameter 
of 5 mm pending for NMR analysis. 1H NMR spec-
tra of all urinary samples were acquired using 
a 600 MHz spectrometer (Bruker Avance III, 
Bruker Biospin, Germany) with 5 mm broadband 
inverse configuration probe with a z axis magnetic 
field-gradient capability operating at 600.13 MHz 
for proton. D2O solvent in the sample buffer was 
used to lock the magnetic field. A standard 
1-dimensional (1-D) NMR pulse [recycle delay 
(RD)-90°-t1-90°-tm-90°-acquire free induction 
decay (FID)] was employed at 300 K for the acqui-
sition of urine spectra. A total of 128 scans were 
recorded into 64 k data points with a spectral width 
of 20 ppm.
Plasma samples were first vortexed before 400 μL 
was combined with 250 μL of saline solution (0.9% 
NaCl w/v, 20% D2O). The mixture was vortexed 
and centrifuged at 16,000 x g for 10 min at 4°C 
before 600 μL of the supernatant was transferred to 
a 5 mm outer diameter NMR tube. A Carr−Purcell 
−Meiboom−Gill (CPMG) pulse sequence 
[RD−90°−( c_ − 180°− c_)n− acquisition] was applied 
to plasma samples at 310 K (2 c_n = 76.8 ms) to 
improve the visualization of signals generated 
from low molecular weight metabolites. A total of 
32 scans were recorded into 72 k data points with 
a spectral width of 20 ppm.
NMR spectral data analysis
1H NMR spectra obtained from the rat samples 
were automatically pre-processed in TopSpin 3.1 
software which included phasing, baseline correc-
tion and referencing to TSP peak in urinary and 
fecal spectra at δ1H 0.00 or the anomeric proton 
from α-glucose at δ1H 5.223 in plasma spectra. The 
high-resolution integration of peaks in the spectra 
creates huge data matrices which require powerful 
software; MATLAB (MathWorks) has been 
employed in this study. The NMR spectra were 
subsequently transferred into MATLAB software 
and digitized into 20 k data points with 
a resolution of 0.0005 ppm. The water peak was 
excised from urinary (δ1H 4.72 and 4.90), fecal 
(δ1H 4.50 and 5.10) and plasma (δ1H 4.50 and 
5.10) spectra to minimize the effect of the remain-
ing baseline distortion caused by imperfect water 
suppression. In addition, regions between δ1H 5.45 
and 6.15 containing urea signals were removed 
from urinary spectra. The pre-processed spectral 
data of urine and feces were aligned to adjust for 
shifts in peak position58 due to small pH differences 
between samples and normalized using median fold 
normalization.59 Citrate (δ1H 2.48 and 2.70) was 
removed from plasma spectra prior to the peak 
alignment and the plasma spectra were not normal-
ized since blood composition is maintained under 
homeostatic control.
The resulting NMR spectra were imported into 
SIMCA 14.0 (Umetrics) to conduct principal com-
ponent analysis (PCA) with a unit variance (UV) 
scaling method, followed by an orthogonal signal 
correction-projection to latent structures- 
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discriminant analysis (O-PLS-DA) in MATLAB 
(R2014a) environment using in-house developed 
scripts. MATLAB was used to generate O-PLS-DA 
coefficient plots, with a color visualization of corre-
lation values (r2) of each variable. Red color indi-
cates higher correlation whilst blue indicates lower 
correlation of the variables with the classification. 
The fitness and predictability of the models 
obtained from OPLS-DA were determined by the 
R2 and Q2 values, respectively. The O-PLS-DA 
models in the current study were established 
based on one PLS component and one orthogonal 
component using mean-centered and UV-scaled 
spectral data sets. Metabolic profiles of urine, feces 
at all time points and peripheral plasma at the last 
time point from both lean and obese Zucker rats 
were correlated with body weight using O-PLS 
regression analysis. Fasting insulin levels from all 
groups were statistically correlated with urinary 
and fecal profiles at the last time point, and the 
portal vein and peripheral plasma profiles using 
O-PLS regression analysis. The validation of all 
O-PLS-DA and O-PLS models involved in this 
study was assessed using 1,000-times permutation 
test. To assist metabolite assignment, J-resolved 
spectroscopy (JRES) was carried out along with 
the use of in-house and public databases.60 
Further assignment of metabolites was also accom-
plished with the use of statistical total correction 
spectroscopy (STOCSY) on 1-D spectra.61
Bile acid profiling
Urine and plasma samples were thawed at 4°C 
overnight and centrifuged at 18,000 g for 15 min 
at 4°C. A total of 100 µL of the supernatant from 
each sample was transferred into 0.5 mL Eppendorf 
96-deepwell plates and 300 µL of ice-cold methanol 
was added to each well for protein precipitation. All 
plates were heat-sealed (Thermo Fisher Scientific, 
Hertfordshire UK), vortexed for 30 min at 4°C 
using an Eppendorf MixMate at 1400 rpm and 
incubated for 20 min at −20°C, followed by centri-
fuging at 3486 g (4500 rpm) for 15 min at 4° 
C. A total of 200 µL of supernatant was transferred 
to Eppendorf 350 µL microplates, which were sub-
sequently heat-sealed with thermo foil prior to 
analysis. Another 20 µL of supernatant from each 
urine or serum sample was pooled together in glass 
beakers to form the quality control (QC) samples 
(total volume = 1420 µL for each type of biofluid). 
A total of 4260 µL of ice-cold methanol was added 
to the glass beaker for protein precipitation accord-
ing to the aforementioned incubation steps. The 
supernatant from the QC sample was transferred 
into multiple wells in the Eppendorf 350 µL 
microplates.
Bile acid profiling was carried out using ACQUITY 
UltraPerformance Liquid Chromatography (UPLC) 
coupled with a Xevo G2-S Q-ToF mass spectrometer 
(Waters Ltd.). The injection volume of all samples 
was 10 μL. To minimize injector carry-over, 3 wash 
cycles of weak (H2O:2-propanol, 9:1, v:v) and strong 
(2-propanol) solvent preparations were performed 
simultaneously with sample analysis. ACQUITY 
BEH C8 column (1.7 μm, 100 mm × 2.1 mm) was 
used at an operating temperature of 60°C. The mobile 
phase A consisted of acetonitrile and water (UPLC 
grade) (1:10, v:v) with 1 mM ammonium acetate and 
pH was adjusted to 4.15 with acetic acid. Mobile 
phase B consisted of acetonitrile and 2-propanol 
(1:1, v:v). The liquid chromatography condition was 
adopted from a previous publication by Sarafian et -
al.62 In brief, the gradient was started with 90% A at 
an initial flow rate of 0.6 mL/min for 0.1 min, fol-
lowed by a linear reduction of A to 65% from 0.1 to 
9.25 min and another further reduction to 15% from 
9.25 to 11.5 min. Between 11.5 and 11.8 min, the flow 
rate was increased to 0.65 mL/min and the solvent 
A was reduced from 15% to 0%. Between 11.8 and 
12.4 min, 100% B was used to wash off the lipidic 
matrix at a flow rate of 0.8–1 mL/min. Between 12.45 
and 15 min, the column was conditioned to the initial 
condition and the flow rate was reduced to 0.6 mL/ 
min. The MS system was equipped with an electro-
spray ionization source operating in negative ion 
mode (ESI−). Mass spectrometry parameters were as 
follows: capillary voltage was set at 1.5 kV, cone 
voltage at 60 V, source temperature at 150°C, deso-
lvation temperature at 600°C, desolvation gas flow at 
1000 L/h, and cone gas flow rate at 150 L/h. Seven 
injections of solvent blanks and 10 injections of the 
QC sample were carried out before the analysis of the 
samples. The QC sample was injected once every 11 
sample injections. Thirteen mixtures of bile acid stan-
dards were injected at the end of the sample run for 
identification. Automatic data dependent acquisition, 
MSE and dynamic range enhancement MS methods 
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were applied to the QC sample for bile acid 
identification.
Bile acid profile analysis
The raw data were converted to NetCDF format 
using Databridge built in MassLynx V4.1 (Waters, 
Inc) and the data were extracted using XCMS pack-
age in R software. The relative levels of the identi-
fied bile acids, reflected by relative peak intensities, 
were analyzed using multiple Student’s t-test.
16S rRNA gene-based sequencing analysis
Bacterial genomic DNA was isolated from gastroin-
testinal content and fecal samples using 
a PowerFecal® DNA isolation kit (MOBIO 
Laboratories, Inc., USA). A total weight of approxi-
mately 0.25 g was transferred to the prefilled-dry 
bead tube followed by the addition of 750 μL of 
bead solution and 60 μL of solution C1 containing 
sodium dodecyl sulfate (SDS) prior to homogeniza-
tion and cell lysis. The mixture was heated at 65°C 
for 10 minutes and subsequently bead-beaten at 
5500 Hz for 2 cycles x 20 seconds. The mixture was 
centrifuged at 13,000 x g for 1 minute and approxi-
mately 400 μL of supernatant was transferred to 
a clean 2 ml collection tube.
DNA sequencing was undertaken by Research 
and Testing Laboratory (Austin, Texas, USA) 
using the Illumina MiSeq. In brief, to determine 
the diversity and structure of the bacterial commu-
nities in different samples, the protocol as pre-
viously described by Caporaso et al.63 was used. 
PCR amplifications were performed with the pri-
mers 515 F (5-GTGCCAGCMGCCGCGGTAA-3ʹ) 
and 806 R (5-GGACTACHVGGGTWTCTAAT- 
3ʹ), which contains a 6-bp error-correcting barcode 
unique to each sample, for the V4 region of the 16S 
rRNA gene. The PCR products from different sam-
ples were quantified using a Qubit 2.0 fluorometer 
(Invitrogen, Carlsbad, CA) and mixed accordingly 
to achieve the equal concentration in the final mix-
ture, which was used to construct PCR amplicon 
libraries. To minimize the impact of potential early 
round PCR errors, 20 independent PCR products 
for each sample were combined to construct PCR 
amplicon libraries. Sequencing was performed on 
an Illumina MiSeq platform.
The 16S rRNA gene sequences were analyzed using 
the bioinformatics software package Mothur and the 
MiSeq SOP Pipeline. 16S rRNA gene sequence reads 
were quality checked and normalized to the lowest 
number of reads in Mothur. To maintain normal-
ization and minimize artifacts, singletons and any 
Operational Taxonomic Units (OTUs), which were 
not found at >10 OTUs in any one sample, were 
collated as OTU singletons and OTU_rare phylo-
types. Using the Vegan package of the R statistical 
package, analysis was performed on the data sets 
contained within the files generated by Mothur (all 
OTUs were defined using a cutoff value of 97%). The 
Unifrac-weighted distance matrix was analyzed in 
R using nonmetric multidimensional scaling ordina-
tion and the shared OTU file was used to determine 
the number of times that an OTU was observed in 
multiple samples, and was used for multivariate ana-
lysis in R. Operational Taxonomic Unit taxonomies 
(from phylum to genus) were determined using the 
RDP MultiClassifier script to generate the RDP tax-
onomy. Alpha and beta indices were calculated from 
these datasets with Mothur and R using the Vegan 
package. The OTU data were subsequently analyzed 
using STAMP.64
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